Investors

Investors

Accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.

We Deliver at a Global Scale

Benefits for all stakeholders

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

See our board of directors and management team

Our Latest Corporate Presentation

Corporate Update and Webcast Replay – February 2023

Press Releases and Corporate Updates

Latest Press Release

Median Technologies announces 2022 revenue of €23.8 million, up 16%, and an order backlog of €60.8 million

January 19, 2023 – Median Technologies announces 2022 revenue of €23.8 million, up 16% vs 2021, an order backlog of €60.8 million and a cash position of €21.5 million as of December 31, 2022.

See all press releases

Latest Corporate Update

Corporate Update and Webcast Replay – February 2023

Download

See all corporate updates

Shareholding Structure as of June 30, 2022

Number of shares: 15,506,199

FURUI Medical Science Company Luxembourg9.72

Celestial Successor Fund LP8.31

Abingworth LLP (nominative and non nominative)6.17

Canon Inc6.20

Founders, Management, Employees4.99

Others64.60

Stock Market Data

Median Technologies is listed on Euronext Growth (ISIN: FR0011049824, ticker: ALMDT)

Share price data

View price chart

Analyst Coverage

Median Technologies is followed by the analysts listed below.

Any opinions, estimates, forecasts and recommendations regarding Median Technologies made by these analysts are their own. These opinions, estimates, forecasts and recommendations may or may not represent those of Median’s management.